25 Result(s)
within
Mathias Witzens-Harig
-
Article
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma
The original version of this article unfortunately contained an error. In the Conflict of interest statement, Anne-Marie Quinson is described as declaring no conflict of interest.
-
Article
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
-
Article
Open AccessHealth-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
Health-related quality of life was a secondary endpoint in the phase III GALLIUM study in previously untreated patients with follicular lymphoma who were treated with rituximab- or obinutuzumab-chemotherapy. P...
-
Article
Open AccessPhase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a tetraspanin transmembrane protein predominantly expressed on normal and malignant B cells. This phase I, open-label study used a modified 3 ...
-
Article
Open AccessTherapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial
Large field irradiation had been standard for early-stage follicular lymphoma (FL) for a long time. Although involved field radiotherapy (IF-RT) was recently favored because of the toxicity of large field irra...
-
Article
The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience
The role of autologous stem cell transplantation (autoSCT) as consolidating treatment for peripheral T-cell lymphoma (PTCL) is unsettled. The aim of this analysis was to investigate the impact of autoSCT in th...
-
Article
HCV load as a possible prognostic factor in patients with HCV-related DLBCL
-
Chapter
Niedrigmaligne Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten
Indolente bzw. niedrigmaligne Non-Hodgkin-Lymphome machen 35–40 % aller Non-Hodgkin-Lymphome aus, unterscheiden sich gegenüber den hochmalignen Lymphomen durch einen häufig über Jahre dauernden nicht aggressiv...
-
Chapter
Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor
The Bruton’s tyrosine kinase (BTK) is an essential in the B-cell receptor (BCR) signaling pathway which was identified as crucial in the pathogenesis of B-cell malignancies. Ibrutinib, a first-in-class BTK inh...
-
Chapter
Ibrutinib
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton’s tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small m...
-
Article
In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study
-
Article
The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin’s lymphomas
Efficacy and safety of rituximab treatment in patients with Hepatitis C virus (HCV) infection associated non-Hodgkin’s lymphoma (NHL) are still disputable. The aim of this study was to evaluate the influence o...
-
Article
Open AccessHigh-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
High-dose (HD) chemotherapy with melphalan and autologous blood stem cell transplantation (ABSCT) for treatment of symptomatic multiple myeloma (MM) on an outpatient basis has been well established in the USA ...
-
Article
Open AccessAnalysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
Skeletal involvement (SI) is observed at low prevalence in patients with diffuse large B-cell lymphoma (DLBCL). Due to the rareness of this particular condition, prospective trials for these patients are scarce.
-
Living Reference Work Entry In depth
Niedrigmaligne Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten
Indolente bzw. niedrigmaligne Non-Hodgkin-Lymphome machen 35–40 % aller Non-Hodgkin-Lymphome aus, unterscheiden sich gegenüber den hochmalignen Lymphomen durch einen häufig über Jahre dauernden nicht aggressiv...
-
Article
Erratum to: Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study
-
Article
Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study
Previous randomized trials have demonstrated that rituximab maintenance (R-maintenance) can prolong time to progressive disease in patients with follicular lymphoma (FL). The phase IIIb MAXIMA study (NCT004303...
-
Article
Sarcoidosis and the occurrence of malignant diseases
Whereas the association between sarcoidosis and malignant diseases has been well described, it remains controversial whether this association is merely a coincidence or the consequence of a common pathophysiol...
-
Article
Open AccessA phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
The current standard treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma (DLBCL) primarily consists of intensified salvage therapy and, if the disease is chemo-sensitive, high ...
-
Article
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
Richard Houlston, Kari Hemminki and colleagues report a meta-analysis of genome-wide association studies of multiple myeloma and identify a variant in the CCDN1 gene that influences risk for develo** a specific...
